Introduction:
On June 21st, 2019, the second ever treatment for hypoactive sexual desire disorder (HSDD) in women was approved by the FDA. The drug, Bremelanotide (Referred in the article as "Bremo" /" Vyleesi") was developed as a combined R&D effort between Palatin Technologies (PTN) and AMAG Pharmaceuticals (AMAG) over a period of 4 years.
An estimated 11.75 million women in the U.S. alone are affected by HSDD. Furthermore, multiple phase 3 clinical trials evaluating the drug's safety and efficacy have definitively proven, in my view, that 1) The drug indeed works